BCG vaccine extensively used even in countries where efficacy against pulmonary tuberculosis is negligible. A number of possible reasons for the variable efficacy of BCG in different countries have been proposed. None have been proven, some have been disproved, and none can explain the lack of efficacy in both low-TB burden countries (US) and high-TB burden countries (India). The reasons for variable efficacy have been discussed at length in a WHO document on BCG. BCG has protective effects against some non-tuberculosis mycobacteria. BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with
Inoculation specific immunity to the virus, while requiring more generations of the virus to reach levels of infection likely to kill the patient. The rising immunity terminates the infection. So the twofold effect is to ensure the less fatal form of the disease is the one caught, and to give the immune system the best start possible in combating it. Inoculation in the East was historically performed by blowing smallpox crusts into the nostril. In Britain, Europe and the American Colonies the preferred method was rubbing material from a smallpox pustule from a selected mild case ("Variola minor") into a scratch